Portrait of Saisimran Datta

saisimran datta 🧫

I'm an MSc Biochemical Engineering student at UCL, working on how biotherapeutics are actually manufactured at scale — process and facility design, scale-up, and the techno-economics that decide whether a product reaches the people who need it. I read Microbiology at Imperial College London, where I worked in Prof. Faith Osier's malaria immunology group on next-generation vaccine candidates. What interests me most is the seam between bioprocess engineering and commercial strategy — platform selection, manufacturing design, market access — and lately the same questions asked from the investment side.

Integrated Bioprocess & Facility Design — ChAdOx1-Vectored Bundibugyo Ebolavirus Vaccine
MSc dissertation, UCL · 2026
Scored six vaccine platforms, from live-attenuated through mRNA and viral-vector, on manufacturability, efficacy, stability, analytical complexity and deployment logistics — concluding that none dominates, and that selection is a trade-off against the outbreak's epidemiological, logistical and regulatory profile. Selected a viral-vector platform on that basis and designed the end-to-end process and facility for one million annual doses: scale-up, equipment design, mass and energy balances, containment and techno-economic evaluation.
Protein Dysregulation in a Triculture Blood–Brain Barrier Model of Chronic Cerebral Malaria
BSc dissertation, Imperial — First Class · 2025
Analysed TEER, permeability, Western blot and ELISA datasets to characterise dysregulation of tight-junction, cytoskeletal, glial and aminopeptidase proteins under chronic infection, then carried the findings through to translation — linking multivalent vaccine design to uptake, access and supply-chain efficiency for malaria vaccines in sub-Saharan Africa.
Hydrohermetic Redesign of Monoclonal Antibody Clarification
MSc, UCL · 2026
Redesigned the clarification train for a mAb process; sizing calculations projected a fourfold reduction in required filtration area, with lower downstream fouling risk.

Bioprocess & engineering — process and facility design, mass and energy balances, equipment sizing, scale-up, containment, techno-economic analysis, GMP.

Laboratory — HPLC, ELISA, Western blot, affinity chromatography, EXPI293 culture and transient transfection, TEER and permeability assays.

Regulatory — CTD-format dossiers, MOHAP and DHA submissions, stability summaries, Certificates of Analysis and Pharmaceutical Product, GMP records.

Data & commercial — R, Python, Excel, statistical analysis; equity and market research, evidence synthesis, executive reporting.

Languages — English, Hindi, Punjabi and Urdu, all fluent.